Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frishman

Showing results (271-280 of 1,859) with videos related to

Pageof 186
Sort By:
Journal of Clinical Pharmacology|July 1, 1990
Co-enzyme Q10: a new drug for cardiovascular diseaseS Greenberg, W H Frishman
American Heart Journal|May 1, 1996
Renin inhibition: a novel therapy for cardiovascular diseaseC Lin, W H Frishman
Journal of Clinical Pharmacology|February 1, 1996
Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertensionA Yu, W H Frishman
Cardiology in Review|August 20, 2009
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapyHouman Khakpour, William H Frishman
Annals of Medicine|May 23, 2000
Serotonin and the heartW H Frishman, P Grewall
American Heart Journal|October 1, 1996
Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatmentW H Frishman, H Hotchkiss
British Journal of Haematology|October 22, 2016
Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapyLiron Frishman-Levy, Shai Izraeli
International Journal of Cardiology|December 1, 1984
Nifedipine in heart failureS Charlap, W H Frishman
Archives of Internal Medicine|July 1, 1983
Verapamil in treatment of chronic stable anginaW H Frishman, S Charlap
Current Atherosclerosis Reports|March 14, 2014
The role of nonpharmacologic device interventions in the management of drug-resistant hypertensionWilliam H Frishman, Daniel Glicklich
Pageof 186

Showing results (271-280 of 1,859) with videos related to

Sort By:
Pageof 186
Journal of Clinical Pharmacology|July 1, 1990
Co-enzyme Q10: a new drug for cardiovascular diseaseS Greenberg, W H Frishman
American Heart Journal|May 1, 1996
Renin inhibition: a novel therapy for cardiovascular diseaseC Lin, W H Frishman
Journal of Clinical Pharmacology|February 1, 1996
Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertensionA Yu, W H Frishman
Cardiology in Review|August 20, 2009
Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapyHouman Khakpour, William H Frishman
Annals of Medicine|May 23, 2000
Serotonin and the heartW H Frishman, P Grewall
American Heart Journal|October 1, 1996
Selective and nonselective dopamine receptor agonists: an innovative approach to cardiovascular disease treatmentW H Frishman, H Hotchkiss
British Journal of Haematology|October 22, 2016
Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapyLiron Frishman-Levy, Shai Izraeli
International Journal of Cardiology|December 1, 1984
Nifedipine in heart failureS Charlap, W H Frishman
Archives of Internal Medicine|July 1, 1983
Verapamil in treatment of chronic stable anginaW H Frishman, S Charlap
Current Atherosclerosis Reports|March 14, 2014
The role of nonpharmacologic device interventions in the management of drug-resistant hypertensionWilliam H Frishman, Daniel Glicklich
Pageof 186